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Objective: With liberalization of donor eligibility criteria, organs are being har-
vested from remote locations, increasing donor ischemic times. Although several
studies have evaluated the effects of prolonged donor ischemic times on short-term
survival and graft function, few have addressed concerns regarding long-term
survival.
Methods: Over the last 11 years, 819 consecutive adults underwent cardiac trans-
plantation at Columbia Presbyterian Medical Center. Recipients were separated into
the following 4 groups based on donor ischemic time: 150 minutes, 150 to 200
minutes, 200 to 250 minutes, and 250 minutes. Statistical analysis included
Kaplan-Meier survival and Cox proportional hazard models to identify predictors of
long-term survival.
Results: Donor ischemic time was 120.1  21.1 minutes for group 1 (n  321),
174.1  14.7 minutes for group 2 (n  264), 221.7  14.6 minutes for group 3 (n
 154), and 295.5  37.1 minutes for group 4 (n  80) (P  .001). There were no
significant differences in recipient age, donor age, etiology of heart failure, United
Network for Organ Sharing status, or history of previous cardiac surgery among the
groups (P NS). Prolonged donor ischemic time did not adversely affect long-term
survival, with actuarial survival at 1, 5, and 10 years of 86.9%, 75.2%, and 56.4%
for group 1; 86.2%, 76.9%, and 50.9% for group 2; 86.4%, 71.0%, and 43.7% for
group 3; and 86.7%, 70.1%, and 50.9% for group 4 (P  .867). There was no
significant difference in freedom from transplant coronary artery disease among the
4 groups (P  .474).
Conclusions: Prolonged donor ischemic time is not a risk factor for decreased
long-term survival. Procurement of hearts with prolonged donor ischemic time is
justified in the setting of an increasing recipient pool with a fixed donor population.
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At New York Presbyterian Hospital–Co-lumbia Medical Center, orthotopic car-diac transplantation has a 1-, 5-, and 10-year survival of 84%, 72%, and 53%,respectively, which is comparable to datareported by other high-volume transplant
centers.1-3 To accommodate increasing demand in the set-
ting of a declining donor population, many transplant pro-
grams have liberalized donor eligibility criteria.4-7 This has
translated into harvesting older hearts, from more unstable
donors, in more remote locations, with the latter resulting in
an increase in donor ischemic time (DIT).8
Although several studies have evaluated the effects of
prolonged DIT on short-term survival and graft function,
few have addressed concerns regarding long-term survival
with a substantial number of patients and adequate fol-
low-up time.9,10 This issue has therefore remained a concern
shared by many transplant centers and has been the subject
of considerable debate. Additionally, there has been some
experimental data implicating prolonged DIT in the devel-
opment of transplant coronary artery disease (TCAD) by
inducing endothelial activation.11,12 However, to the best of
our knowledge, there have not been any clinical studies that
have evaluated this issue in a large group of patients with
long-term follow-up.
To help clarify the effects of DIT on long-term survival
and development of TCAD, we retrospectively analyzed our
transplant experience over the last decade. This study con-
stitutes a large single-center transplant experience, with
long-term follow-up, evaluating the effect of prolonged DIT
on long-term survival and development of TCAD.
Patients and Methods
From January 1992 through January 2003, 937 patients underwent
cardiac transplantation at New York Presbyterian Hospital–Co-
lumbia Medical Center. Pediatric recipients (18 years at the time
of transplantation, n  118) were excluded. The remaining 819
adult recipients were separated into the following 4 groups based
on length of DIT: group 1,150 minutes (39.2%, n 321); group
2, 150 to 199 minutes (32.2%, n  264); group 3, 200 to 249
minutes (18.8%, n 154); and group 4,250 minutes (9.8%, n
80). Group 4 contained 17 patients (2.1%) with DIT  300
minutes and 6 patients (0.7%) with DIT  360 minutes. All 819
recipients were included in the analysis, even patients who died in
the early postoperative period. DIT was defined as the interval
from application of donor aortic crossclamp to release of the
recipient crossclamp.
Detection of Transplant Coronary Artery Disease
All patients underwent annual coronary angiography to evaluate
for transplant coronary artery disease. The diagnosis was based on
the following: (1) discrete lesions resulting in 50% obstruction
of the proximal or midportion of major graft vessels, or (2) diffuse,
concentric narrowing of whole vessels, including their branches.
Reports of “luminal irregularities” were considered positive for
TCAD, while reports of “mild tapering of coronary artery” were
considered negative studies. If a patient had TCAD, the frequency
of angiography was increased to biannually. Patients were not
given routine vasodilators before coronary injections. All angio-
grams were reviewed by a cardiologist and compared with the
previous year’s films to detect the presence of luminal irregulari-
ties, discrete stenoses, loss of third-order branches, or pruning of
vessels.
Donor Acceptance Criteria
Donor and recipients were matched for ABO blood type compat-
ibility and size (generally within 20% of body weight). Prospective
human leukocyte antigen (HLA) matching was not used with the
exception of recipients with high levels of panel reactive anti-HLA
antibodies (20%) who underwent a prospective cross-match.
Male donors less than 40 years of age and female donors less than
45 years of age met criteria as suitable donors provided there was
no evidence of preexisting heart disease or impaired myocardial
dysfunction by echocardiography. Older individuals also met cri-
teria as suitable donors provided that coronary atherosclerotic
lesions could be excluded, ideally by cardiac catheterization. In-
dividuals with serologies positive for HIV, hepatitis B (hepatitis B
sAg), hepatitis C, or nonprimary brain cancer were excluded from
being donors.
Graft Procurement
Donor hearts were harvested from heart-beating, brain-dead indi-
viduals. Graft procurement and preservation were performed using
cold University of Wisconsin solution (Viaspan; DuPont Pharma-
ceuticals, Wilmington, Del) and topical hypothermia. Prior to
1996, orthotopic cardiac transplantation was performed using the
biatrial technique described by Lower and Shumway.13,14 Since
1996, almost all transplants were performed using the bicaval
anastomosis technique.15,16
Immunosuppressive Regimen
Until January 1996, all patients received cyclosporine, steroids,
and azathioprine. Dosing of cyclosporine consisted of a preoper-
ative oral dose of 3 to 6 mg/kg, followed by an intravenous dose
of 1 to 2 mg/kg every 24 hours until oral intake was tolerated.
Daily oral doses of 3 to 6 mg/kg were adjusted to maintain a serum
level of 300 to 350 mg/mL. After 6 to 12 months, cyclosporine
doses were reduced to maintain a serum level between 100 and 150
ng/mL. Azathioprine was also administered preoperatively as an
oral dose of 4 mg/kg, followed by daily doses of 2 mg/kg, with
adjustments in dosing made based on the patients’ white blood cell
count, platelet count, and hepatic function.
Since 1996, mycophenolate mofetil, starting at a dose of 1000
mg twice daily, replaced azathioprine as part of cyclosporine-
based therapy. Intravenous methylprednisolone (500 mg) was ad-
ministered during the operation and postoperatively with 125 mg
every 8 hours for 3 doses. Prednisone was then instituted at a daily
dose of 1 mg/kg and gradually tapered over 4 months to 0.1
mg/kg/d. Intravenous murine monoclonal antibody OKT3 (5 mg/d)
took the place of cyclosporine for the first 4 days after transplan-
tation for patients with severe renal dysfunction. Beginning in
1998, induction therapy using dacluzimab was added to our im-
munosuppression regimen in certain patients.
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Exclusion Criteria
Exclusion criteria for cardiac transplantation were factors that
adversely impact long-term survival (eg, cancer), increase periop-
erative morbidity and mortality (eg, pulmonary hypertension, re-
cent pulmonary embolus, active infection), or affect a patient’s
ability to care for him- or herself (eg, untreated major psychiatric
illness, recent substance abuse). Pretransplant pulmonary hyper-
tension, defined as greater than 6 Woods units, was also considered
to be a relative contraindication to transplantation. Many of these
comorbidities, however, are being reevaluated, given our favorable
experience in transplanting patients once perceived to be high risk
(eg, diabetics).
Statistical Analysis
Data were represented as frequency distributions and percentages.
Values of continuous variables were expressed as a mean 
standard deviation (SD). Continuous variables were compared
using paired t tests, whereas categorical variables were compared
by means of chi-squared tests. For all analyses, a P value of .05
was considered statistically significant. Kaplan-Meier analysis was
used to calculate survival along with a log-rank P value when
comparing groups. Actuarial survival at 1, 3, 5, and 10 years
posttransplant was calculated by constructing life tables. Signifi-
cant predictors of survival were identified using multivariate Cox
proportional hazard models. To further examine the relationship
between prolonged DIT, advanced donor age, and survival, donor
age was stratified into 3 ranges: 35, 35 to 49, and 50 years.
Survival for each donor age group was then plotted within DIT
groups 1 to 4. All data were analyzed utilizing SPSS 11.5 (SPSS
Inc, Chicago, Ill).
Results
Distribution of Prolonged DIT throughout the 11-Year
Study Period
Overall mean DIT throughout the 11-year period was 173.8
 58.7 (42.4-396.2). The distribution of patients with pro-
longed DIT was fairly equal during the course of the study
period. The number of patients with associated prolonged
DIT was 11 (13.8%) in 1992, 4 (5.0%) in 1993, 9 (11.3%)
in 1994, 4 (5.0%) in 1995, 10 (12.5%) in 1996, 9 (11.3%) in
1997, 13 (12.6%) in 1998, 6 (7.5%) in 1999, 8 (10.0%) in
2000, 3 (3.8%) in 2001, and 3 (5.4%) in 2002.
Demographics
Recipient characteristics. Table 1 outlines baseline clin-
ical demographics of patients in each of the 4 DIT groups.
There was no significant difference in recipient age, gender,
race, or etiology of heart failure among patients in the 4 DIT
groups (P  NS). Mean pulmonary artery pressures were
also similar among the groups (29.2  11.8 mm Hg for
TABLE 1. Clinical characteristics of patients
Group 1 Group 2 Group 3 Group 4 P
Recipient data
Patient distribution 321 (39.2%) 264 (32.2%) 154 (18.8%) 80 (9.8%) .031
Age (y) 51.9 11.6* 52.1 12.2 52.7 11.6 49.5 14.2 .453†
Range of ages (y) 18.8-67.1 18.3-70.3 19.1-70.4 20.7-66.2 .451
Gender
Male 241 (75.0%) 203 (76.9%) 121 (78.6%) 59 (73.8%) .833
Female 80 (25.0%) 61 (23.1%) 33 (21.4%) 21 (26.3%)
Race
Caucasian 246 (76.6%) 214 (81.1%) 119 (77.3%) 54 (67.5%) .238
African American 42 (13.1%) 28 (10.6%) 23 (14.9%) 7 (8.8%) .635
Other 33 (10.3%) 22 (8.3%) 12 (7.8%) 19 (23.8%) .061
P value .249† .618 .037 .371
Etiology of ESHD
CAD 191 (59.5%) 148 (56.1%) 85 (55.2%) 46 (57.5%) .534
ICM 106 (33.0%) 99 (37.5%) 60 (39.0%) 28 (35.0%) .612
Other 24 (7.5%) 17 (6.4%) 9 (5.8%) 6 (7.5%) .720
UNOS status
1 262 (81.6%) 214 (81.1%) 128 (83.1%) 63 (78.8%) .957
2 59 (18.4%) 50 (18.9%) 26 (16.9%) 17 (21.3%) .976
Donor data
Age (years) 32.5 12.8* 32.1 12.3 32.4 13.4 30.2 14.1 .701
Age range (years) 10.2-63.3 10.1-59.5 7.5-62.7 4.2-63.3
DIT (minutes) 120.1 21.1* 174.1 14.7 221.7 14.6 295.5 37.1 .001
DIT range (minutes) 42.1-149.9 150.0-199.9 200.0-249.9 250.0-396.2 .451
ESHD, End-stage heart disease; CAD, coronary artery disease; ICM, idiopathic cardiomyopathy; UNOS, United Network for Organ Sharing; DIT, donor
ischemic time.
*Mean  standard deviation.
†Variables were compared using ANOVA testing.
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group 1, 27.7  10.9 mm Hg for group 2, 30.3  12.1 mm
Hg for group 3, and 32.0  13.1 mm Hg for group 4; P 
.153).
United Network for Organ Sharing (UNOS) status dis-
tribution was similar for all 4 groups, with UNOS status 1
and 2 recipients distributed as 81.6% and 18.4% in DIT
group 1, 81.1% and 18.9% in DIT group 2, 83.1% and
16.9% in DIT group 3, and 78.8% and 21.3% in DIT group
4 (P  NS).
There was no significant difference among the 4 DIT
groups in the percentage of patients who underwent previ-
ous cardiac surgery. One hundred forty-nine (46.4%) pa-
tients in group 1, 139 (52.7%) patients in group 2, 79
(51.3%) patients in group 3, and 41 (51.3%) patients in
group 4 underwent previous cardiac surgery before trans-
plantation. The most common types of surgeries are listed in
Table 2.
Donor characteristics. There was no statistically signif-
icant difference in donor age among the groups (P  NS;
Table 1). DIT was similar when comparing male recipient
and female recipients (174.5  58.5 versus 171.5  59.3
minutes, respectively; P  .596) and recipient races (172.9
 56.8 for Caucasian, 173.0  60.7 for African American,
and 181.5  69.5 for other; P  .214).
Survival
Overall survival of the entire cohort is depicted in Figure 1.
Actuarial survival at 1, 5, and 10 years was 86.5%, 73.4%,
and 50.3%, respectively, with median survival of 10.2
years. There was no significant difference in overall survival
when comparing the 4 DIT groups (P  .867; Figure 2).
Actuarial survival at 1, 5, and 10 years was 86.9%, 75.2%,
and 56.4% for group 1; 86.2%, 76.9%, and 50.9% for group
2; 86.4%, 71.0%, and 43.7% for group 3; and 86.7%,
70.1%, and 50.9% for group 4, respectively (Table 3). When
group 4 was compared with groups 1 to 3, there was no
difference in survival (P  .196). Actuarial survival at 1, 5,
and 10 years posttransplant for the subgroup of patients
within group 4 with DIT 300 minutes was 82.2%, 71.7%,
and 46.9%, respectively. There was no statistically signifi-
cant difference in survival when this subgroup of patients
was compared with the remainder of patients in DIT group
4 (P  .514) or with patients in DIT groups 1 to 3 (P 
.442).
Relationship Between Donor Age, DIT, and Survival
Four hundred fifty-eight (55.9%) patients received heart
from donors 35 years of age, 272 (33.2%) from donors 35
to 49 years, and 89 (10.9%) from donors 50 years. The
distribution of hearts from donors of advanced age (50
years) among the 4 DIT group was not significantly differ-
ent and encompassed 11.5% (n 37) of patients in group 1,
10.2% (n  27) of group 2, 10.4% (n  16) of group 3, and
11.3% (n  9) of group 4 (P  .182). When separating
recipients in each on the 4 DIT groups based on 3 donor age
ranges (35, 35 to 49, and50 years), advanced donor age
adversely impacted survival in DIT groups 1 and 3 (P 
.024 and P  .038, respectively), but not groups 2 and 4 (P
 .315 and P  .692, respectively; Figures 3, 4).
Predictors of Survival
Univariate analysis. By univariate analysis, recipient
gender, race, and donor age were statistically significant risk
factors adversely affecting long-term survival (Table 4).
DIT was not an independent predictor of decreased survival
(P  .353).
Mutivariate analysis. Using Cox proportional hazard
models, only recipient female gender was found to be a
statistically significant predictor adversely affecting long-
term survival (OR 1.281, 95% CI 0.856-1.694, P .001, SE
0.158; Table 5).
Primary Graft Failure
There was no significant difference in the incidence of
primary graft failure (PGF) among the 4 groups (P  NS).
PGF occurred in 2 (0.6%) patients in DIT group 1, 7 (2.7%)
patients in group 2, 6 (3.9%) patients in group 3, and 2
(2.5%) patients in group 4 (P  .114).
Relationship between Prolonged DIT and Development
of Transplant Coronary Artery Disease
There was no statistically significant difference in freedom
from TCAD when comparing the 4 DIT groups, although
TABLE 2. Previous cardiac surgeries for each cohort
Group 1 Group 2 Group 3 Group 4 P
Previous cardiac surgery 149 (46.4%) 139 (52.7%) 79 (51.3%) 41 (51.3%) .671
CABG 44 (13.7%) 42 (15.9%) 29 (18.8%) 20 (25.0%)
LVAD 73 (22.7%) 58 (22.0%) 32 (20.8%) 9 (11.3%)
OHT 18 (5.6%) 12 (4.5%) 7 (4.5%) 1 (1.3%)
MVR 3 (0.9%) 3 (1.1%) 0 3 (3.8%)
AVR 2 (0.6%) 1 (0.4%) 1 (0.6%) 0
CABG, Coronary artery bypass grafting; LVAD, left ventricular assist device; OHT, orthotopic heart transplant; MVR, mitral valve replacement; AVR, aortic
valve replacement.
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the incidence of TCAD was highest for patients in group 4
(P  .474; Figure 5). Freedom from TCAD at 1, 5, and 10
years was 98.0%, 68.9%, and 38.9% for group 1; 98.1%,
60.1%, and 38.5% for group 2; 95.7%, 70.5%, and 42.1%
for group 3; and 98.8%, 57.7%, and 28.9% for group 4.
When group 4 was compared with groups 1 to 3 as a
composite, the difference in freedom from TCAD was still
not statistically significant (P  .202), although median
Figure 1. Overall posttransplant survival for all adult patients from January 1992 through January 2003. Median
survival was 10.2 years.
Figure 2. Survival for each DIT group. There was no significant difference in overall survival when comparing the
4 DIT groups. Median survival was 12.4 years for group 1, 10.2 years for group 2, 8.8 years for group 3, and 11.4 years
for group 4.
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time for development of TCAD was 5.3 years for group 4,
as compared with 8.3 years for groups 1 to 3 (Figure 6).
Impact of Donor Heart Left Ventricular Hypertrophy
on Survival
Data regarding donor left heart ventricular hypertrophy
(LVH) were available to us beginning only in 1996. There
were a total of 17 patients since 1996 who received hearts
noted to have LVH on echocardiography. There was no
statistically significant difference in graft function or sur-
vival when comparing these 17 patients with LVH to other
patients without LVH since 1996. These 17 patients in-
cluded 9 (6.9%) from DIT group 1, 3 (2.8%) from group 2,
4 (5.2%) from group 3, and 1 (1.6%) from group 4.
Discussion
Due to the overwhelming demand for organs, the definition
of the “ideal donor organ” is in constant flux. In an attempt
to expand the donor pool and accommodate patients await-
ing transplantation, it has become commonplace to accept
organs from distant locations, resulting in prolongation of
DIT.
Some series have demonstrated prolonged DIT to be
associated with significantly reduced postoperative left ven-
tricular ejection fraction (LVEF), right ventricular function,
and increased requirement for inotropes within the first 48
hours postoperatively.5,8 This may be secondary to a more
elaborate cytokine response or ischemia-reperfusion injury.5
Prolonged DIT has also been associated with a trend toward
increased intensive care unit and hospital stay.5,8 However,
many transplant centers believe that although prolonged
DIT may have negative consequences in the immediate
postoperative period, it may not adversely affect long-term
survival.
The data on the impact of prolonged DIT on short- and
mid-term survival are conflicting. Several studies have not
found prolonged DIT to be an independent predictor of
adverse outcome.4,8,15-17 Del Rizzo and colleagues,4 report-
ing on 372 patients, found that prolonged DIT (defined as
240 minutes) did not adversely affect posttransplant
1-year survival. Additionally, Plugfelder and associates,17
in a series of 167 heart recipients, found no difference in
90-day graft loss or 3-month survival for recipients with
prolonged DIT (300 minutes). When Plugfelder and col-
leagues18 updated their experience on 219 patients, they
again found that prolonged DIT (3 hours) did not ad-
versely impact 1-year survival. Another comparative study
by Mullen and coworkers19 demonstrated no significant
difference in 30-day or 90-day survival when comparing
261 recipients with DIT above and below 4 hours. However,
30- and 90-day mortality was 13% and 16%, respectively,
for recipients with DIT  4 hours compared with 7% and
10%, respectively, for patients with DIT  4 hours (P 
.014 and 0.027, respectively). Finally, Korner and col-
leagues20 showed no difference in survival based on pro-
longed DIT (up to 330 minutes) at a mean follow-up time of
22 months, although data was only available for 100/834
(12.0%) patients.
Two multi-institutional studies, however, reported by the
Cardiac Transplant Research Database Group, concluded
that prolonged DIT was an independent risk factor for early
mortality after transplantation.21-23 These studies had a
mean follow-up of 13.9 and 8.1 months, respectively.
Although there have been several studies analyzing the
effect of prolonged DIT on short- and mid-term survival,
there are only a few single-institutional studies that have
studied the effect of prolonged DIT on long-term survival
with a substantial number of patients.4,18,24-26 Furthermore,
a detailed examination of the literature reveals that there
have not been any studies with a substantial number of
patients that have evaluated the effects of prolonged DIT of
up to 5 hours on survival. The largest single-center series to
evaluate the effect of prolonged DIT on survival studied a
total of 373 patients and only evaluated prolonged DIT up to
4 hours.4 This study did not analyze whether or not DIT 
5 hours adversely affected survival.
While multicenter registries have the advantage of being
able to pool data on large numbers of patients and enhance
statistical power, they are limited by interinstitutional vari-
ability and accurate risk stratification.27,28 Furthermore, reg-
istries are generally composed of data from many low-
volume transplant centers and relatively few high-volume
centers.29 Conclusions are made from extrapolation of data
from many centers, where there may be significant differ-
ences in management strategies and ranges of experienc-
es.24 It is possible, therefore, that favorable results of a
single large-institution experience may be masked by results
from smaller centers with higher mortality rates.24
In our report of more than 800 patients over 11 years, we
demonstrated that prolonged DIT did not significantly affect
long-term survival. Prolonged DIT was evaluated for up to
5 hours in a cohort of 17 patients, a subgroup of patients in
DIT group 4. We demonstrated that DIT can be safely
extended to 5 hours without adversely affecting survival, a
finding that to the best of our knowledge has not yet been
published in the literature in a substantial number of pa-
tients.
Our investigation of the relationship between prolonged
DIT and TCAD did not corroborate experimental data,
TABLE 3. Actuarial survival for each DIT group
1 year
(%)
3 years
(%)
5 years
(%)
10 years
(%)
Median
(%)
DIT Group 1 86.2 81.0 76.9 50.9 12.4
DIT Group 2 86.9 83.5 75.2 56.4 10.2
DIT Group 3 86.4 79.8 71.0 43.7 8.8
DIT Group 4 86.7 81.8 70.1 50.9 11.4
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which suggests that prolonged DIT may be implicated in the
development of TCAD.11,12,30 It should be noted, however,
that there was a greater incidence of TCAD in patients with
prolonged DIT (although not statistically significant).
There is some evidence that prolonged DIT, in combi-
nation with donor heart LVH, can be a risk factor for
reduced graft function and survival.31 Because data regard-
ing donor LVH was available to us beginning only in 1996,
our evaluation of this issue was limited. Although we dem-
onstrated that there was no statistically significant differ-
ence in graft function or survival when comparing the 17
patients with LVH to other patients without LVH since
1996, we could not effectively evaluate the combined ef-
fects of donor heart LVH and prolonged DIT since there
was only 1 patient who met these criteria.
Limitations of this study include those related to a ret-
rospectively performed analysis. Identification of demo-
graphic variables, DIT, and risk factors for mortality were
obtained by chart review, which has inherent limitations,
such as access and accuracy of the data. Additionally, as a
retrospective observational study, it is subject to selection
bias and incomplete data collection. Although comparative
data of the clinical characteristics indicate that DIT groups
1 to 4 were similar for several donor and recipient charac-
teristics, as outlined in Tables 1 and 2 (recipient age, gender,
race, etiology of heart failure, UNOS status, donor age, and
previous cardiac surgical history), it is likely that there were
additional factors that were not apparent but that may have
had an important effect on the results. Additionally, inter-
pretation of the results regarding the effects of advanced
donor age on survival and the relationship between ad-
vanced donor age and prolonged DIT is limited because of
the relatively small sample size of hearts from donors  50
years. Although we demonstrated that advanced donor age
adversely impacted survival only in DIT groups 1 and 3, not
groups 2 and 4, it is possible that if a larger cohort of
recipients who received hearts from donors 50 years were
studied by conducting a multi-institutional analysis, a dif-
ferent result may have been obtained. Finally, interpretation
of the data regarding the relationship between prolonged
DIT and development of TCAD may also be limited for the
similar reason. Given the relatively small number of patients
in group 4, it is possible that if a multi-institutional evalu-
ation of development of TCAD in patients with prolonged
DIT was conducted, increasing the number of patients with
prolonged DIT, a statistically significant association might
have been observed.
In conclusion, in our experience with 819 adult recipients
over 11 years, prolonged DIT did not significantly affect
long-term survival. Patients with DIT  5 hours demon-
strated similar short- and long-term survival as patients with
DIT of shorter durations. Additionally, prolonged DIT was
not a significant risk factor for the development of TCAD.
These data have emphasized to our team that DIT can safely
be extended beyond 5 hours and have made us more secure
with our efforts to expand the donor pool by harvesting
Figure 3. Effect of donor age on survival within DIT group 1. Advanced donor age adversely affected survival within
DIT group 1, with median survival for patients with donor age < 35, 35 to 49, and >50 years of 11.4, 8.8, and 7.5
years, respectively.
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hearts from distant locations with associated prolonged
DIT.
We could not perform a statistical analysis on our rela-
tively limited experience with DIT  6 hours given the
limitations of small sample sizes and statistical power.
However, it may be time to expand the criteria for DIT to
include hearts with DIT 6 hours and evaluate the effect of
DIT  6 hours on survival, possibly by pooling data from
a multicenter study. This would better define the limit to the
duration that we can safely extend DIT without adversely
affecting outcome.
We believe that suitability of donor hearts from distant
locations should be evaluated on a case-by-case basis. Vari-
ables such as donor stability, inotropic use, and left ventric-
ular function should be considered in the decision of
whether to accept or reject a donor heart. Associated pro-
longed DIT should not, in and of itself, be an excluding
factor given the similar long-term survival when comparing
groups with different DIT. Moreover, hearts with associated
prolonged DIT should not be exclusively reserved for
sicker, unstable patients, as some have suggested.21-23 In
our series, there was not a tendency to implant hearts with
Figure 4. Effect of donor age on survival within DIT group 3. Advanced donor age adversely affected survival within
DIT group 3, with median survival for patients with donor age < 35, 35 to 49, and >59 years of 10.4, 10.1, and 7.2
years, respectively.
TABLE 4. Univariate analysis of factors affecting survival
Variable P*
Recipient age .946
Recipient gender .012†
Recipient race
Caucasian .054
African American .043†
Other .686
CMV .805
MFM .466
LVAD .778
DM .309
Donor age .034†
DIT .353
DIT Group 1 .659
DIT Group 2 .847
DIT Group 3 .431
DIT Group 4 .434
CMV, Cytomegalovirus; MFM, male-female mismatch; LVAD, left ventricu-
lar assist device; DM, diabetes mellitus; DIT, donor ischemic time.
*P value from Cox Regression univariate analysis.
†P  .005.
TABLE 5. Factors affecting survival by Cox proportional
hazard models
Variable OR 95% CI P SE
Recipient
gender
1.281 0.856-1.694 .001 0.158
OR, Odds ratio; CI, confidence interval; SE, standard error.
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prolonged DIT into sicker recipients, as confirmed by the
similar distribution of UNOS status across DIT groups. This
may have been a contributing factor to the similarity in
outcome. We believe that in view of the current donor
shortage, attempts to increase the donor pool by evaluating
donor hearts associated with prolonged ischemic times is
warranted.
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